The FDA shortage determinations that supported widespread compounded semaglutide and tirzepatide availability resolved in 2025
FDA approvals in 2025 increasingly aligned with pivotal, practice-changing data signaling genuine late-stage productivity rather than volume-driven progress
Clinical Trials Friedreich's Ataxia (FA) and Spinocerebellar Ataxia FA COMS A Study of the Clinical Progression of FA in concert with the Friedreich's Ataxia Research Alliance (FARA) Network FFA Biomarker Study A Study of New Tools to Measure and Track the Clinical progression of FA (including new gait and balance measures) Intravenous Immunoglobulin Therapy in FA and SCA3 Study of the Natural History of SCA types 1,2,3 & 6 Parkinson's Disease (PD) and Essential Tremor (ET) Vesicare for Urinary Incontinence in PD Cognitive Aging in PD Patients Constipation and PD A Therapeutic Study for Progressive Supranuclear Palsy (PSP) Treatment of Dyskinesias in PD TETRAS Primidone for the treatment of ET
All you need is a smartphone, tablet, or computer to engage with our proficient semaglutide providers
[4] According to NICE guideline NG12, women aged 55 years and over with PMB should be referred urgently under the suspected cancer pathway (younger post-menopausal women may be referred based on clinical judgement and risk factors)
Heart rate increases slightly more with tirzepatide (average 2-3 bpm) than with semaglutide, but this change has not translated to increased cardiac events in published trials
